Willow Biosciences Stock Current Liabilities
| WLLW Stock | CAD 0.03 0.01 25.00% |
Willow Biosciences fundamentals help investors to digest information that contributes to Willow Biosciences' financial success or failures. It also enables traders to predict the movement of Willow Stock. The fundamental analysis module provides a way to measure Willow Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Willow Biosciences stock.
As of the 24th of January 2025, Total Current Liabilities is likely to grow to about 2.2 M. Also, Non Current Liabilities Total is likely to grow to about 2.3 M. Willow | Current Liabilities |
Willow Biosciences Company Current Liabilities Analysis
Willow Biosciences' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Willow Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Willow Biosciences is extremely important. It helps to project a fair market value of Willow Stock properly, considering its historical fundamentals such as Current Liabilities. Since Willow Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Willow Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Willow Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Willow Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Willow Biosciences has a Current Liabilities of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and about the same as Health Care (which currently averages 0.0) industry. The current liabilities for all Canada stocks is 100.0% higher than that of the company.
Willow Biosciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Willow Biosciences from analyzing Willow Biosciences' financial statements. These drivers represent accounts that assess Willow Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Willow Biosciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 46.1M | 95.9M | 14.2M | 12.4M | 11.2M | 19.8M | |
| Enterprise Value | 27.7M | 80.9M | 3.9M | 11.4M | 10.3M | 14.8M |
Willow Fundamentals
| Return On Equity | -2.12 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | (1.41) % | ||||
| Current Valuation | 5.23 M | ||||
| Shares Outstanding | 144.2 M | ||||
| Shares Owned By Insiders | 24.30 % | ||||
| Number Of Shares Shorted | 120.38 K | ||||
| Price To Earning | 4.00 X | ||||
| Price To Book | 22.19 X | ||||
| Price To Sales | 2.35 X | ||||
| Revenue | 1.17 M | ||||
| Gross Profit | (3.28 M) | ||||
| EBITDA | (11.63 M) | ||||
| Net Income | (13.03 M) | ||||
| Cash And Equivalents | 11.01 M | ||||
| Cash Per Share | 0.19 X | ||||
| Total Debt | 2.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 16.20 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | (10.92 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (0.05) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 19 | ||||
| Beta | 1.14 | ||||
| Market Capitalization | 4.33 M | ||||
| Total Asset | 6.67 M | ||||
| Retained Earnings | (121.69 M) | ||||
| Working Capital | 2.36 M | ||||
| Net Asset | 6.67 M |
About Willow Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Willow Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Willow Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Willow Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Willow Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Willow Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Willow Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Willow Stock
Moving against Willow Stock
| 0.73 | GOOG | Alphabet CDR Earnings Call This Week | PairCorr |
| 0.72 | AMZN | Amazon CDR Earnings Call This Week | PairCorr |
| 0.6 | WMT | Walmart Inc CDR | PairCorr |
| 0.41 | MSFT | Microsoft Corp CDR Earnings Call This Week | PairCorr |
| 0.31 | AAPL | Apple Inc CDR Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Willow Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Willow Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Willow Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Willow Biosciences to buy it.
The correlation of Willow Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Willow Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Willow Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Willow Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Willow Stock
Willow Biosciences financial ratios help investors to determine whether Willow Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Willow with respect to the benefits of owning Willow Biosciences security.